Objective: To evaluate success rate and factors affecting the success of radioactive iodine (RAI) ablation in low-risk of recurrence well-differentiated thyroid carcinoma patients. Methods: Retrospective review of medical records was done in 132 low-risk of recurrence well-differentiated thyroid cancer (WDTC) patients between January 2007 and December 2013. All patients underwent 1) total thyroidectomy or equal surgery and 2) pre-ablative evaluationwith 99mTc-pertechnetate thyroid scan and 24-hour 131I thyroid uptake. RAIablation using low activity (30 mCi: n = 17) or high activity (80 or 100 mCi: n = 115) were given. Success rate of each activity and a comparison of success rates between 2 doses were analyzed. Criteria of successful ablati...
Radioactive iodine ablation therapy is a standard treatment for most patients with differentiated th...
Radioactive iodine ablation therapy is a standard treatment for most patients with differentiated th...
Abstract: Aim: Recombinant human thyroid-stimulating hormone (rhTSH) has been approved in Europe as ...
Objective: To evaluate outcome of radioactive iodine (RAI) ablation/treatment in pathologically defi...
Purpose: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation w...
Recently, the potential of remnant thyroid ablation using 1,110 MBq 131I has been established, albei...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
Purpose: Following total thyroidectomy of differentiated thyroid carcinoma (DTC), some patients are ...
A record revtew study on the success of radioiodine ablation in postoperative well differentiated t...
Objectives: Currently, little is known about the prognostic significance of achieving successful abl...
Background. Radioactive iodine (RAI) ablation is recommended for most patients with differentiated t...
Contains fulltext : 153820.PDF (publisher's version ) (Open Access)INTRODUCTION: P...
Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carci...
Radioactive iodine ablation therapy is a standard treatment for most patients with differentiated th...
Radioactive iodine ablation therapy is a standard treatment for most patients with differentiated th...
Abstract: Aim: Recombinant human thyroid-stimulating hormone (rhTSH) has been approved in Europe as ...
Objective: To evaluate outcome of radioactive iodine (RAI) ablation/treatment in pathologically defi...
Purpose: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation w...
Recently, the potential of remnant thyroid ablation using 1,110 MBq 131I has been established, albei...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
Purpose: Following total thyroidectomy of differentiated thyroid carcinoma (DTC), some patients are ...
A record revtew study on the success of radioiodine ablation in postoperative well differentiated t...
Objectives: Currently, little is known about the prognostic significance of achieving successful abl...
Background. Radioactive iodine (RAI) ablation is recommended for most patients with differentiated t...
Contains fulltext : 153820.PDF (publisher's version ) (Open Access)INTRODUCTION: P...
Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carci...
Radioactive iodine ablation therapy is a standard treatment for most patients with differentiated th...
Radioactive iodine ablation therapy is a standard treatment for most patients with differentiated th...
Abstract: Aim: Recombinant human thyroid-stimulating hormone (rhTSH) has been approved in Europe as ...